August, 2021 - Rapha Capital Management, LLC

johnfinn In Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

Encouraging data confirming activity in a solid tumor indication presented on first nine patients at low dose cohorts in ongoing...

johnfinn In Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Dan Tetzl In IMAGIN Medical, Portfolio, Rapha Capital Management

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

Rapha Capital BioVentures Fund I, LP (RCBVFI) managed by Rapha Capital leads the financing. Kevin Slawin, M.D., a leading urooncologist...

Dan Tetzl In IMAGIN Medical, Portfolio, Rapha Capital Management

IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing

Rapha Capital BioVentures Fund I, LP (RCBVFI), Leads New Convertible Note Financing Kevin Slawin, MD, a Leading UroOncologist and Manager...

August 2021

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing

Categories

Archives